172 CHAPTER 8 81. Yu HT, Yang PS, Jang E, Kim TH, Uhm JS, Kim JY, et al. Label adherence of direct oral anticoagulants dosing and clinical outcomes in patients with atrial fibrillation. J Am Heart Assoc. 2020;9(12):e014177. 82. Bando S, Nishikado A, Hiura N, Ikeda S, Kakutani A, Yamamoto K, et al. Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: analysis of the Shikoku rivaroxaban registry trial (SRRT). J Cardiol. 2018;71(2):197–201. 83. Bang OY, On YK, Lee MY, Jang SW, Han S, Han S, et al. The risk of stroke/systemic embolism and major bleeding in Asian patients with nonvalvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: results from a real-world data analysis. PLoS One. 2020;15(11):e0242922. 84. Barra ME, Fanikos J, Connors JM, Sylvester KW, Piazza G, Goldhaber SZ. Evaluation of dose-reduced direct oral anticoagulant therapy. Am J Med. 2016;129(11):1198–204. 85. Bastida C, Corominas N, Sotoca JM, Rovira M. Anticoagulation in atrial fibrillation: NOAC prescribing in primary health care. Int J Clin Pharm. 2017;39(2):478–82. 86. Brook R, Aswapanyawongse O, Tacey M, Kitipornchai T, Ho P, Lim HY. Real-world direct oral anticoagulant experience in atrial fibrillation: falls risk and low dose anticoagulation are predictive of both bleeding and stroke risk. Intern Med J. 2020;50(11):1359–66. 87. Chao TF, Hong KS, Lee BC, De Caterina R, Kirchhof P, Reimitz PE, et al. Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. J Chin Med Assoc. 2021;84(5):485–90. 88. Eschler CM, Woitok BK, Funk GC, Walter P, Maier V, Exadaktylos AK, et al. Oral anticoagulation in patients in the emergency department: high rates of off-label doses, no difference in bleeding rates. Am J Med. 2020;133(5):599–604. 89. Gustafson WL, Saunders J, Vazquez SR, Jones AE, Witt DM. Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation. Pharm Pract (Granada). 2019;17(4):1709. 90. Ionin VA, Bliznuk O, Baranova E, Shlyakhto E. Anticoagulant therapy in patients with nonvalvular atrial fibrillation in real clinical practice: in appropriate dose reductions. Rational Pharmacotherapy in Cardiology. 2021;17(2):206–11. 91. Kartas A, Samaras A, Vasdeki D, Dividis G, Fotos G, Paschou E, et al. Flaws in anticoagulation strategies in patients with atrial fibrillation at hospital discharge. J Cardiovasc Pharmacol Ther. 2019;24(3):225–32. 92. Kilickiran Avci B, Vatan B, Ozden Tok O, Aidarova T, Sahinkus S, Uygun T, et al. The trends in utilizing nonvitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation: a real-life experience. Clin Appl Thromb Hemost. 2016;22(8):785–91. 93. Kimmons LA, Kabra R, Davis M, Segars B V, Oliphant CS. Dabigatran use in the real world: a multihospital system experience. J Pharm Pract. 2014;27(4):384–8. 94. Larock AS, Mullier F, Sennesael AL, Douxfils J, Devalet B, Chatelain C, et al. Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. Ann Pharmacother. 2014;48(10):1258–68. 95. Lee KN, Choi JI, Boo KY, Kim DY, Kim YG, Oh SK, et al. Effectiveness and safety of off-label dosing of non–vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients. Sci Rep. 2020;10(1):1801. 96. Lodziński P, Gawałko M, Budnik M, Tymińska A, Ozierański K, Grabowski M, et al. Trends in antithrombotic management of patients with atrial fibrillation. Pol Arch Intern Med. 2020;130(3):196–205. 97. Masunaga N, Abe M, Ogawa H, Aono Y, Ikeda S, Doi K, et al. Current status, time trends and outcomes of combination therapy with oral anticoagulant and antiplatelet drug in patients with atrial fibrillation: the Fushimi AF registry. Circ J. 2018;82(12):2983–91.
RkJQdWJsaXNoZXIy MTk4NDMw